Gilead Sciences v NuCana: Lessons for parallel UK and EPO proceedings
In a UK Patents Court case decided earlier this year, Gilead Sciences v NuCana, Gilead sought revocation of the UK designations of two of NuCana’s European patents, EP 2955190B1 and EP 3904365B1, from the same family. These patents covered NuCana’s anti-cancer drug acelarin. NuCana counterclaimed that their patents were infringed by Gilead’s anti-viral products containing the compound sofosbuvir.